{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:53Z","timestamp":1787246693940,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01839-2","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:18:59Z","timestamp":1783016339000},"page":"4139-4153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis"],"prefix":"10.1007","volume":"16","author":[{"given":"Jeffrey","family":"Crowley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eingun James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvas","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Leoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"19","key":"1839_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"2","key":"1839_CR2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.12788\/cutis.0701","volume":"111","author":"NP Del Toro","year":"2023","unstructured":"Del Toro NP, Wu JJ, Han G. New treatments for psoriasis: an update on a therapeutic frontier. Cutis. 2023;111(2):101\u20134.","journal-title":"Cutis"},{"issue":"9","key":"1839_CR3","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s13555-022-00775-1","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Xia Q, John AR, Patel V, Seigel L. Treatment patterns for targeted therapies, non-targeted therapies, and drug holidays in patients with psoriasis. Dermatol Ther (Heidelb). 2022;12(9):2087\u2013103.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1839_CR4","first-page":"CD011535","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10148","key":"1839_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"1","key":"1839_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"issue":"10198","key":"1839_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"1","key":"1839_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","volume":"12","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, et al. Long-term benefit\u2013risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(1):167\u201384.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1839_CR9","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1111\/jdv.17003","volume":"35","author":"K Hansel","year":"2021","unstructured":"Hansel K, Zangrilli A, Bianchi L, Peris K, Chiricozzi A, Offidani A, et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021;35(3):e169\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1839_CR10","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1111\/jdv.17656","volume":"36","author":"K Hansel","year":"2022","unstructured":"Hansel K, Zangrilli A, Bianchi L, Peris K, Chiricozzi A, Offidani A, et al. A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. J Eur Acad Dermatol Venereol. 2022;36(2):e111\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1839_CR11","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s13555-025-01420-3","volume":"15","author":"D Thaci","year":"2025","unstructured":"Thaci D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, et al. Correction: Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis: interim analysis from the VALUE global prospective post-marketing observational study at 25 months. Dermatol Ther (Heidelb). 2025;15(6):1595\u20137.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1839_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40257-025-00964-6","volume":"26","author":"KA Papp","year":"2025","unstructured":"Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Gooderham M, et al. Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: final LIMMitless phase 3, open-label extension trial results. Am J Clin Dermatol. 2025;26(5):829\u201341.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1839_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","volume":"189","author":"LF Stein Gold","year":"2023","unstructured":"Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol. 2023;189(5):540\u201352.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1839_CR14","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s13555-024-01293-y","volume":"14","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Soliman AM, Gisondi P, Fang S, Patel M, Strober B. Matching-adjusted indirect comparison of risankizumab versus deucravacitinib in patients with moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb). 2024;14(11):3071\u201381.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1839_CR15","doi-asserted-by":"publisher","DOI":"10.25251\/h9van576","volume":"9","author":"N Magnolo","year":"2026","unstructured":"Magnolo N, Soung J, Frew J, Costanzo A, Llamas-Velasco M, Bukhalo M, et al. A phase 4 multicenter, randomized, open-label, efficacy assessor-blinded study of risankizumab compared with deucravacitinib for the treatment of adult patients with moderate plaque psoriasis who are candidates for systemic therapy: 16-week results from IMMpactful. J Skin [Internet]. 2026;9(6):s631.","journal-title":"J Skin [Internet]"},{"issue":"10510","key":"1839_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","volume":"406","author":"LS Gold","year":"2025","unstructured":"Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363\u201374.","journal-title":"Lancet"},{"issue":"6","key":"1839_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"5","key":"1839_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/jrsm.1653","volume":"14","author":"B Truong","year":"2023","unstructured":"Truong B, Tran LT, Le TA, Pham TT, Vo TT. Population adjusted-indirect comparisons in health technology assessment: a methodological systematic review. Res Synth Methods. 2023;14(5):660\u201370.","journal-title":"Res Synth Methods"},{"issue":"11","key":"1839_CR19","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s13555-023-00977-1","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Park SH, Patel V, Hogan M, Wang WJ, Davidson D, et al. Matching-adjusted indirect comparison of the long-term efficacy of deucravacitinib versus adalimumab for moderate to severe plaque psoriasis. Dermatol Ther (Heidelb). 2023;13(11):2589-603.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"1839_CR20","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jdv.16521","volume":"34","author":"B Strober","year":"2020","unstructured":"Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1839_CR21","doi-asserted-by":"crossref","unstructured":"Gold LS, Armstrong AW, Soung J, Vender RB, Cantero \u00c1G, Hoffmann M, et al. Durability of response with icotrokinra, a targeted oral peptide, in adults with moderate-to-severe plaque psoriasis: one-year results from the phase 3, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials 2026 [updated March 28, 2026]. https:\/\/eposters.aad.org\/s3\/AM2026\/poster\/73228\/Durability+of+Response+With+Icotrokinra+a+Targeted+Oral+Peptide+in+Adults+With+Moderate-to-Severe+Plaque+Psoriasis+One-Year+Results+From+the+Phase+3+Placebo-+and+Active+Comparator-Controlled+ICONIC-ADVANCE+1++ICONIC-ADVANCE+2+Trials.pdf. Accessed 28 Mar 2026.","DOI":"10.1016\/j.jaad.2026.04.698"},{"key":"1839_CR22","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. www.cochrane.org\/handbook. Accessed 28 Mar 2026."},{"issue":"1","key":"1839_CR23","doi-asserted-by":"publisher","first-page":"2169574","DOI":"10.1080\/09546634.2023.2169574","volume":"34","author":"J Signorovitch","year":"2023","unstructured":"Signorovitch J, Diels J, Van Sanden S, Schubert A, Hassan F, Thilakarathne P, et al. Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. J Dermatol Treat. 2023;34(1):2169574.","journal-title":"J Dermatol Treat"},{"key":"1839_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jdin.2023.12.012","volume":"15","author":"RG Langley","year":"2024","unstructured":"Langley RG, Sanyal C, Situ A, Alulis S, Hassan F, Peterson S, et al. Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: change in baseline Psoriasis Area and Severity Index from week 4 to 40. JAAD Int. 2024;15:165\u20137.","journal-title":"JAAD Int"},{"issue":"12","key":"1839_CR25","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/1346-8138.17448","volume":"51","author":"TF Tsai","year":"2024","unstructured":"Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, et al. Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: a systematic literature review and network meta-analysis. J Dermatol. 2024;51(12):1559\u201371.","journal-title":"J Dermatol"},{"issue":"10","key":"1839_CR26","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, Pinter A, Warren RB, Puig L, et al. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther (Heidelb). 2024;14(10):2841\u201357.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1839_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol. 2020;19(5):487\u201392.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1839_CR28","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s13555-023-01028-5","volume":"13","author":"RR McLean","year":"2023","unstructured":"McLean RR, Sima AP, Beaty S, Jones EA, Eckmann T, Low R, et al. Durability of near-complete skin clearance in patients with psoriasis using systemic biologic therapies: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023;13(11):2753\u201368.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1839_CR29","doi-asserted-by":"publisher","unstructured":"Soriano ER, Acosta-Felquer ML, Mazzuoccolo LD. Predicting and preventing clinical psoriatic arthritis. Best Pract Res Clin Rheumatol. 2026;102133. https:\/\/doi.org\/10.1016\/j.berh.2026.102133","DOI":"10.1016\/j.berh.2026.102133"},{"issue":"3","key":"1839_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaad.2025.05.912","volume":"93","author":"B Strober","year":"2025","unstructured":"Strober B, Patel M, Bialik B, St John G, Garg V, Kang H-J, et al. 63027 incidence of psoriatic arthritis in biologic-naive psoriasis patients achieving national psoriasis foundation\u2019s treat to target goals: a real-world study with the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2025;93(3):230.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1839_CR31","first-page":"310","volume":"39","author":"M Schmidt","year":"2026","unstructured":"Schmidt M, Dowdle TS, Golovko G, Munoz A. Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators. Proc (Bayl Univ Med Cent). 2026;39(2):310\u20134.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"1839_CR32","unstructured":"Merola JF. Risankizumab treatment is associated with lower risk of developing psoriatic arthritis in patients with psoriasis compared to other targeted immunomodulators. Spring European Academy of Dermatology and Venerology; May 7\u20139; Athens, Greece; 2026."},{"issue":"1","key":"1839_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.12039","volume":"168","author":"RJ Thorneloe","year":"2013","unstructured":"Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20\u201331.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1839_CR34","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13555-025-01474-3","volume":"15","author":"B Strober","year":"2025","unstructured":"Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, et al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025;15(9):2409\u201321.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1839_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40273-013-0126-6","volume":"32","author":"A Torbica","year":"2014","unstructured":"Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1839_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","volume":"310","author":"AG Florek","year":"2018","unstructured":"Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271\u2013319.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1839_CR37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1839_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s13555-023-01089-6","volume":"14","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, et al. Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey. Dermatol Ther (Heidelb). 2024;14(2):421\u201339.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1839_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2339440","volume":"35","author":"SD Smith","year":"2024","unstructured":"Smith SD, Fifer S, Edwards M, Walter A, Zhong Y, Zhuo J, et al. Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia. J Dermatol Treat. 2024;35(1):2339440.","journal-title":"J Dermatol Treat"},{"key":"1839_CR40","unstructured":"Phillipo DM, Dias S, Palmer S, Abrams KR, Welton NJ. Nice DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE 2016. https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/population-adjusted. Accessed 28 Mar 2026."},{"issue":"6","key":"1839_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/17407745241244788","volume":"21","author":"KM Higgins","year":"2024","unstructured":"Higgins KM, Levin G, Busch R. Considerations for open-label randomized clinical trials: design, conduct, and analysis. Clin Trials. 2024;21(6):681\u20138.","journal-title":"Clin Trials"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01839-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:45Z","timestamp":1787243385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01839-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jeffrey Crowley has received grant\/research support from AbbVie, Amgen, Arcutis, Janssen, Novartis, Merck, Lilly, Pfizer, UCB, MC2 Therapeutics, Verrica, Sandoz, and Regeneron; has participated in speakers\u2019 bureaus for AbbVie,, Janssen,, Sun Pharma,, and UCB; and has served as a consultant for AbbVie, Janssen, Sanofi-Genzyme, Regeneron, UCB, Amgen, and Arcutis. Eingun J. Song (EJS) has served as a consultant, promotional speaker and\/or investigator for AbbVie, Alphyn, Alumis, Amgen, Apogee, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Dermbiont, Galderma, Incyte, Johnson & Johnson, Lilly, LEO, Moon Lake, Novartis, Organon, Ortho-Dermatologics, Oruka, Pfizer, Regeneron, Sanofi, SUN Pharma, UCB, Veradermics, Takeda, Target Registry, Timber, Zura Bio. EJS is a senior editor for the Journal of Psoriasis and Psoriatic Arthritis. Linda F. Stein-Gold has received grants and personal fees from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira\/UCB, Eli Lilly, Janssen Biotech, Leo Pharma, Novartis, Pfizer, Regeneron, Sun Pharma, Taro, and Valeant. Paolo Gisondi has been a consultant and\/or speaker for AbbVie, Almirall, Amgen, Janssen, Leo-pharma, Eli Lily, Novartis, Pierre Fabre, Sandoz, Sanofi, and UCB. Christopher G. Bunick has served as an investigator and\/or consultant for AbbVie, AbSci, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Disc Medicine, Eli Lilly, EPI Health\/Novan, Galderma, Highlight Therapeutics, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Priovant, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, UCB, and Veradermics. Richard Ta is an AbbVie contractor. Blair Kaplan, Vishvas Garg, Emanuele Leoncini, Bang Truong, and Dolly Sharma are employees of AbbVie Inc. and may hold stock options. Bruce Strober has served as a consultant (received honoraria) for AbbVie, Alumis, Almirall, Amgen, Apogee, Arcutis, Bristol-Myers-Squibb, CorEvitas, Dimagi, Immunovant, Johnson & Johnson, Leo, Eli Lilly, Neurocrine, Novartis, Oruka, Meiji Seika Pharma, Protagonist, Pfizer, UCB Pharma, Regeneron, Sanofi-Genzyme, selectION, Takeda. He owns stock options in Mindera Health, selectION. He has served as a speaker for AbbVie, Arcutis, Eli Lilly, Incyte, Johnson & Johnson, Regeneron, Sanofi-Genzyme; and as a co-scientific director (with a consulting fee) for the CorEvitas Psoriasis Registry. He is an investigator for CorEvitas Psoriasis and GPP Registries, Oruka, and Incyte.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All six trials included in this study were conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines, the Declaration of Helsinki, and applicable local guidelines and regulations. Approvals were obtained from local ethics committees of the relevant countries, and written informed consent was obtained from patients at study initiation. This analysis utilized de-identified data from publications and did not require ethics committee approval.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}